These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10803764)

  • 1. Normalization of hematocrit in hemodialysis patients does not affect silent ischemia.
    Conlon PJ; Kovalik E; Schumm D; Minda S; Schwab SJ
    Ren Fail; 2000 Mar; 22(2):205-11. PubMed ID: 10803764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure.
    Conlon PJ; Kovalik E; Schumm D; Minda S; Schwab SJ
    Ren Fail; 2000; 22(4):435-44. PubMed ID: 10901181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin.
    Besarab A; Bolton WK; Browne JK; Egrie JC; Nissenson AR; Okamoto DM; Schwab SJ; Goodkin DA
    N Engl J Med; 1998 Aug; 339(9):584-90. PubMed ID: 9718377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
    Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
    Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA
    N Engl J Med; 1998 Aug; 339(9):578-83. PubMed ID: 9718376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.
    Chen HH; Tarng DC; Lee KF; Wu CY; Chen YC
    J Nephrol; 2008; 21(4):543-9. PubMed ID: 18651544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project.
    McClellan WM; Frankenfield DL; Wish JB; Rocco MV; Johnson CA; Owen WF;
    Am J Kidney Dis; 2001 May; 37(5):E36. PubMed ID: 11325701
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dialysis facility ownership and epoetin dosing in patients receiving hemodialysis.
    Thamer M; Zhang Y; Kaufman J; Cotter D; Dong F; Hernán MA
    JAMA; 2007 Apr; 297(15):1667-74. PubMed ID: 17440144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major declines in epoetin dosing after prospective payment system based on dialysis facility organizational status.
    Thamer M; Zhang Y; Kaufman J; Kshirsagar O; Cotter D; Hernán MA
    Am J Nephrol; 2014; 40(6):554-60. PubMed ID: 25592645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States.
    Wright DG; Wright EC; Narva AS; Noguchi CT; Eggers PW
    Clin J Am Soc Nephrol; 2015 Oct; 10(10):1822-30. PubMed ID: 26358266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of treating the renal anemia in chronic hemodialyzed patients by epoietin alpha and beta.
    Ostrvica E; Mesic E; Ostrvica D; Delic J; Delic-Custendil S; Hukic F
    Med Arh; 2010; 64(1):4-6. PubMed ID: 20422814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of epoetin dose on hematocrit.
    Cotter D; Zhang Y; Thamer M; Kaufman J; Hernán MA
    Kidney Int; 2008 Feb; 73(3):347-53. PubMed ID: 18004296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current management of anemia in adult hemodialysis patients with end-stage renal disease.
    Frankenfield DL; Johnson CA
    Am J Health Syst Pharm; 2002 Mar; 59(5):429-35. PubMed ID: 11887409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
    Driver PS
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease.
    Ifudu O; Feldman J; Friedman EA
    N Engl J Med; 1996 Feb; 334(7):420-5. PubMed ID: 8552143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severity of AIDS and the response to EPO in uremia.
    Ifudu O; Matthew JJ; Mayers JD; Macey LJ; Brezsnyak W; Reydel C; McClendon E; Surgrue T; Rao S; Friedman EA
    Am J Kidney Dis; 1997 Jul; 30(1):28-35. PubMed ID: 9214398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
    Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
    Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.